"The Pink Sheet"  NDA Pipeline  Health News Daily  Other FDC Pubs.    "The Pink Sheet" PharmAsia News "The Pink Sheet" DAILY "The Gray Sheet" "The Tan Sheet" "The Rose Sheet" "The Gold Sheet" "The Silver Sheet" Pharmaceutical Approvals Health News Daily FDAAdvisoryCommittee
		search within: All Publications Medicare Drug Focus "The Blue Sheet" "The Gold Sheet" "The Gray Sheet" Medicare Guide "The Pink Sheet" "The Pink Sheet DAILY" "The Rose Sheet" "The Silver Sheet" "The Tan Sheet" Health News Daily Pharmaceutical Approvals Research Policy ALERT Washington Fax   A D V E R T I S E M E N T  June 2008 Volume 13, Number 6  Pfizer Trying A Novel Oncology Business Unit To Maximize Its Novel Pipeline With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms that show significant promise. Now the company is trying a novel business arrangement to try to make the most of what it has.... Read More>> From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline ... Read More>> AVADO Presented At ASCO; But After The Fanfare, What Does It Signify? With the positive results of Roche’s AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab’s use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting. ... Read More>> Medivation Looks Beyond PSA For MDV3100 Prostate Cancer Endpoints ... Read More>> FLEX Shows Erbitux Strength In NSCLC, CRYSTAL Offers KRAS Biomarker ... Read More>> Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO ... Read More>> Bristol/Medarex Ipilimumab Toxicity Signals Efficacy, Investigator Says ... Read More>> AstraZeneca/Infinity Speed Hsp90 Inhibitor IPI-504 Into Phase III For GIST ... Read More>> R&D In Brief: Oncology ... Read More>> FDA Cleared Ixempra Despite Doubts Over Chance Of Showing Survival Benefit Doubts about the likelihood that the improvement in progression-free survival seen in a pivotal trial of Bristol-Myers Squibb's Ixempra (ixabepilone) will translate to an overall survival advantage could add to the controversy over the appropriateness of PFS as a surrogate for survival in metastatic breast cancer.... Read More>> Ixempra Clinical Development ... Read More>> Ixempra FDA Reviewers ... Read More>>   Wyeth predicts quick response to Tygacil "approvable" letter   Novo Nordisk submits liraglutide in U.S., Europe   GlaxoSmithKline files casopitant for two indications, three regimens   Lilly Cymbalta keeps growing in pain states   April 2008 Approvals  ... Read More>>     April 2008 Supplements  ... Read More>>     April 2008 Abbreviated  ... Read More>>     Biologics Approved In 2008... Read More>>     Estimated FDA User Fee Review Goals For Pending NDAs/BLAs... Read More>>     New Molecular Entities Approved In 2008... Read More>>     Advisory Committee Recommendations... Read More>>     "Approvables" & "Complete Reviews"... Read More>>

© 2008 FDC Reports | Privacy Policy | Terms of Use
	FDC Reports is the publisher of "The Pink Sheet"; "The Pink Sheet" DAILY; "The Gray Sheet"; FDAAdvisoryCommittee.com; "The Tan Sheet"; "The Rose Sheet"; Pharmaceutical Approvals Monthly; "The Gold Sheet"; "The Silver Sheet"; Health News Daily; PharmAsia News, an Elsevier company.